Nachrichten zur Eli Lilly & Co. Aktie

HSBC downgrades Eli Lilly over valuation worry and strong competition

Shares have advanced about 15% in 2025.…

Stocks making the biggest moves premarket: Boeing, Dominos Pizza, Eli Lilly, Progressive and more

These are the stocks posting the largest moves in premarket trading.…

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?

Investor focus is likely to be on the sales numbers of LLYs tirzepatide medicines Mounjaro and Zepbound.…

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)

Investor focus is likely to be on the sales numbers of LLYs tirzepatide medicines Mounjaro and Zepbound.…

The Best Stock to Buy With Less Than $60 in the Market Sell-Off

Plenty of stocks with attractive businesses trade on the market for hundreds of dollars per share -- or more. However,…

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release

Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Massive Investment in US Manufacturing Triggers Wave of Career Opportunities

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and…

Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly…

Stocks making the biggest moves premarket: Boeing, Tesla, BP, Eli Lilly and more

These are the stocks posting the largest moves in premarket trading.…

Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his…

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lillys weight-loss drug Zepbound and its diabetes…

Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note

Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.…

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However,…

These companies have announced their intention to increase US manufacturing

Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor Group and others.…

Eli Lilly im Pivotal-Point-Check: Abnehmpille feiert Studienerfolg - Nadelfreie Revolution für Gewichtsverlust und Diabetes!

Eli Lilly ist der Top-Profiteur nadelfreier Alternativen auf dem boomenden Markt für Gewichtsverlust und Diabetes. Veröffentlichung der Studiendaten zu…

Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since…

Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around…

Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, J&J in focus

…

Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging

…

Prediction: Eli Lillys Newest GLP-1 Drug Will Be a Game-Changer for the Stock @themotleyfool #stocks $LLY

…

Prediction: Eli Lillys Newest GLP-1 Drug Will Be a Game-Changer for the Stock

Drugmaker Eli Lilly (NYSE: LLY) hasnt been exempt from the recent market pullback, but its stock shot higher following the…

Is Eli Lilly Stock a Buy Right Now?

The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration.…

Eli Lillys Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure…

Where Will Eli Lilly Be in 5 Years? @themotleyfool #stocks $MRK $LLY $JNJ $PFE $NVO

…

Eli Lilly: Cementing Its GLP-1 Empire With Orforgliprons Promising Phase 3 Results

…

Stocks making the biggest moves midday: Eli Lilly, Alphabet, Hertz, UnitedHealth and more

These are the stocks posting the largest moves in midday trading.…

Weight-loss pill breakthrough sends Eli Lilly stock surging

The major pharmaceutical company has a new obesity drug on the horizon.…

Eli Lilly gelingt Durchbruch! Die experimentelle GLP-1-Pille half Diabetikern beim Abnehmen und senkte dabei auch ihren Blutzuckerspiegel

Der Arzneimittelhersteller Eli Lilly gab am 17.04.2025 bekannt, dass eine experimentelle Pillenform beliebter GLP-1-Medikamente Menschen mit Typ-2-Diabetes nach 40 Wochen…

Eli Lilly shares surge on new obesity pill data. What it means for the stock from here

Jim Cramer said Eli Lillys new trial data has turned the obesity market into a one-horse race.…

Eli Lilly: Ein Phase-III-Erfolg mit der neuen Abnehmpille lässt den Kurs explodieren!

Der Markt für GLP-1-Produkte soll sich in den nächsten Jahren rasant entwickeln. Laut MarketsandMarkets könnte er von 47,4 Mrd. USD…

Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success By Investing.com

Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success…

Stocks making the biggest moves premarket: Hertz, UnitedHealth, Eli Lilly and more

These are the stocks posting the largest moves in premarket trading.…

Eli Lillys weight loss pill succeeds in first late-stage trial on diabetes patients

The results bring Eli Lillys pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight…

Lilly pill leads to 7.9% weight loss in late-stage trial, shares jump

Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest…

Eli Lilly shares surge on strong trial results for weight-loss pill

Eli Lilly and Co (NYSE:LLY) shares jumped 12% in premarket trading on Thursday after the drugmaker said its experimental weight-loss…

Healthy Returns: What drugmakers are saying about Trump’s looming pharmaceutical tariffs

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its…

Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.…

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading…

Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ:…

NVO, LLY, GPCR & VKTX Stocks Gain Following PFEs Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate,…

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.…

Notable analyst calls this week: Apple, Eli Lilly and Verizon stocks among top picks

…

Top Research Reports for Eli Lilly, American Express & Thermo Fisher

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American Express Company…

Following pledges from Lilly and J&J, Novartis unveils $23B US investment to beef up manufacturing, R&D

On the heels of similar investment pledges by Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to…

Hims Weight Loss Expansion: Real Growth or Just Hype?

[content-module:CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made an…

WDH/EU-Behörde: Kein grünes Licht für Alzheimer-Medikament

(Wirkstoffname berichtigt: 1. Absatz, 2. Satz: Donanemab (statt Donemab).) AMSTERDAM (dpa-AFX) - Die…

EU-Behörde: Kein grünes Licht für Alzheimer-Medikament

AMSTERDAM (dpa-AFX) - Die EU-Arzneimittelbehörde EMA hat kein grünes Licht für die Zulassung eines Alzheimer-Medikaments von…

Pharmakonzern Lilly beendet 2024 überraschend stark - Prognose bestätigt

INDIANAPOLIS (dpa-AFX) - Ein florierendes Geschäft mit seinen Diabetes- und Abnehmmitteln hat dem US-Pharmahersteller Lilly 2024…

Pharmakonzern Lilly erlöst 2024 weniger als gedacht

INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly ist 2024 trotz eines Spurts vor Jahresende nicht so…

Pharmakonzern Lilly erhöht Dividende und kündigt weiteren Aktienrückkauf an

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly plant in den kommenden Jahren weiter Aktien im Milliardenvolumen…